Acrobiosystems Co

Acrobiosystems Co Tax Expense

The Income Tax Expense of Acrobiosystems Co (301080.SZ) as of Oct 24, 2026 is 4.48 M CNY. In the previous year, Income Tax Expense was 4.87 M CNY — a change of -8.06% (lower).

Tax Expense

4.48 MCNY

YoY

-8.06%

Last updated:

Income Tax Expense of Acrobiosystems Co is 2025 4.48 M CNY. Income Tax Expense of Acrobiosystems Co was 2024 4.87 M CNY. It decreases by -8.06% lower compared to the previous year.

The Acrobiosystems Co Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
668,300.00 CNY
Jan 1, 2019
1.58 M CNY
Jan 1, 2020
17.94 M CNY
Jan 1, 2021
22.00 M CNY
Jan 1, 2022
15.77 M CNY
Jan 1, 2023
13.12 M CNY
Jan 1, 2024
4.87 M CNY
Jan 1, 2025
4.48 M CNY
The Acrobiosystems Co Tax Expense history
YEARTax ExpenseYoY
4.48 MCNY-8.06%
4.87 MCNY-62.85%
13.12 MCNY-16.84%
15.77 MCNY-28.31%
22.00 MCNY+22.66%
17.94 MCNY+1,037.62%
1.58 MCNY+135.94%
668,300.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Income Tax Expense of Acrobiosystems Co is 4.48 M CNY in 2025.

Income Tax Expense of Acrobiosystems Co changed from 4.87 M CNY to 4.48 M CNY, representing a -8.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co